Isolation of stable regulatory t cells and uses thereof
AssigneesStichting Sanquin Bloedvoorziening, Stichting Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
InventorsDerk AMSEN, Eloy CUADRADO GODIA, Jannetje Geertruida BORST
Life of this patent
Estimating the term…
Abstract
The invention relates to isolated populations of CD4+GPA33high regulatory T cells, to methods for detecting and/or isolating CD4+GPA33high cells, methods for enriching for CD4+GPA33high cells and to uses of CD4+GPA33high cells and populations of such cells. The invention further relates to methods for classifying an individual suffering from cancer and typing a tumor sample as well as for determining the etiology of autoimmune diseases.
Claims12
-34. (canceled)
A method for enriching a population of cells for regulatory T cells comprising:
- a. contacting a population of cells with an agent capable of binding glycoprotein A33 (GPA33),
- b. determining binding of said cells to said agent capable of binding GPA33, and
- c. selecting and/or isolating CD4+ T cells that have a level of expression of GPA33 that is higher than the average level of expression of GPA33 in said population of cells.
A method for isolating regulatory T cells, the method comprising isolating CD4+ glycoprotein A33 (GPA33)high T cells from a cell sample.
An isolated population of cells wherein at least 75% of the cells are CD4+GPA33high regulatory T cells.
A method for suppressing an immune response and/or for treatment, alleviation or prevention of graft versus host disease (GVHD), transplant rejection, a chronic inflammatory condition or an autoimmune disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of CD4+GPA33high T cells or a population of cells wherein at least 75% of the cells are CD4+GPA33high regulatory T cells.
Dependencies are inferred from the claim text.